Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Celldex: Update Based on 2Q, 2016 Conference Call (CLDX, Neutral, $4.45)

Investment View

Celldex has a broad array of clinical trials underway or in planning that involve five drugs. However, most of…
Read more…

Comments on Agenus, Neuralstem and Celldex

SmithOnStocks Mailbox
About the Mailbox:
My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Celldex Pipeline Update and Investment Thesis (CLDX, Moving from Buy to Hold, $28.56)

Overview
This report updates my investment thinking on Celldex and also provides a brief overview of its two late stage products.…
Read more…